Global Heart Failure Drugs Market 2018-2022

Global Heart Failure Drugs Market 2018-2022

About Heart Failure Drugs

The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.

Technavio’s analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global heart failure drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of heart failure drugs.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Heart Failure Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Amgen
• AstraZeneca
• Bayer
• Novartis


Other prominent vendors
• Gilead
• GlaxoSmithKline
• Pfizer
• Teva Pharmaceutical industries

Market driver

• Rising geriatric population
• For a full, detailed list, view our report

Market trend

• Investment inclination toward developing countries
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

Press Release

Technavio Announces the Publication of its Research Report – Global Heart Failure Drugs Market 2018-2022

Technavio recognizes the following companies as the key players in the global heart failure drugs market: Amgen, AstraZeneca, Bayer, and Novartis.

Other Prominent Vendors in the market are: Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China; and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.”

According to the report, one of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.

Companies Mentioned

Amgen, AstraZeneca, Bayer, Novartis, Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.